<?xml version="1.0" encoding="ISO-8859-1"?>
<?xml-stylesheet type="text/xsl" href="helma.xsl"?>
<xmlroot xmlns:hop="http://www.helma.org/docs/guide/features/database">
  <hopobject id="2432" name="Page" prototype="Page" created="1363280116832" lastModified="1542944326038">
  <hop:parent idref="0" prototyperef="Root"/>
    <http_browser>Mozilla/4.0 (compatible; MSIE 6.0; Windows NT 5.1; SV1)</http_browser>
    <lang>en-us</lang>
    <uri>bone-update</uri>
    <http_host>127.0.0.1:8080</http_host>
    <time type="date">23.11.2018 03:38:46 UTC</time>
    <pseudoparent idref="0" prototyperef="Root"/>
    <http_remotehost>127.0.0.1</http_remotehost>
    <hopsession>127.0.0.r7ysyd9x25u5</hopsession>
    <user>default</user>
    <pvcount type="float">85.0</pvcount>
    <body>I want to make a withdrawal &lt;a href=&quot;https://www.tarokasongbad.com/viagra-mas-barato-e3c4.pdf#development&quot;&gt;acheter du viagra sans ordonnance a paris&lt;/a&gt;  &quot;We are pleased that both Phase III studies met their primary efficacy endpoints and that Study 171 also achieved its other main objective of demonstrating comparability between the Gen2 and MedTone inhalers,&quot; said Mann in a statement. &quot;The positive results of Study 171 and Study 175 will form the basis of an amendment to our new drug application for Afrezza, which we expect to submit to the Food and Drug Administration early in the fourth quarter of this year.&quot;
 </body>
    <http_language>en-US,en;q=0.8</http_language>
    <is_xhtml type="boolean">true</is_xhtml>
    <http_referer>http://beagleboard.org/bone-update/edit</http_referer>
  </hopobject>
</xmlroot>
